Aspire Biopharma Holdings (ASBP) Current Taxes (2022 - 2023)
Aspire Biopharma Holdings (ASBP) posted quarterly Current Taxes of $152689.0 for Q1 2023, up 367.1% year-over-year from $32689.0 in Q1 2022, and up 24.45% quarter-over-quarter from $122689.0 in Q4 2022.
Aspire Biopharma Holdings (ASBP) Current Taxes (2022 - 2023) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Current Taxes for 2 consecutive years, with $152689.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Current Taxes rose 367.1% year-over-year to $152689.0; the TTM figure through Mar 2023 stood at $152689.0 (up 367.1% YoY), while the FY2022 annual figure was $122689.0, changed N/A from the prior year.
- Current Taxes climbed to $152689.0 in Q1 2023 per ASBP's latest filing, from $122689.0 in the prior quarter.
- Across five years, Current Taxes topped out at $152689.0 in Q1 2023 and bottomed at $32689.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 49.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 76.32 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 152,689.00 |
| Dec 31, 2022 | 122,689.00 |
| Sep 30, 2022 | 92,689.00 |
| Jun 30, 2022 | 62,689.00 |
| Mar 31, 2022 | 32,689.00 |